These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 22088702)

  • 21. Tolerability of two different combinations of antiretroviral drugs including tenofovir used in occupational and nonoccupational postexposure prophylaxis for HIV.
    Burty C; Prazuck T; Truchetet F; Christian B; Penalba C; Salmon-Ceron D; Yazdanpanah Y; May T; Rabaud C
    AIDS Patient Care STDS; 2010 Jan; 24(1):1-3. PubMed ID: 20095911
    [No Abstract]   [Full Text] [Related]  

  • 22. Tenofovir: a pill to prevent HIV?
    Bonn D
    Lancet Infect Dis; 2005 Feb; 5(2):78. PubMed ID: 15702509
    [No Abstract]   [Full Text] [Related]  

  • 23. HIV transmission may be prevented by intravaginal tenofovir ring.
    Parks L
    Future Med Chem; 2012 Dec; 4(18):2239. PubMed ID: 23359902
    [No Abstract]   [Full Text] [Related]  

  • 24. Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial.
    Succop SM; MacQueen KM; van Loggerenberg F; Majola N; Karim QA; Karim SS
    AIDS Care; 2014; 26(12):1521-5. PubMed ID: 25285564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on microbicide research and development - seeking new HIV prevention tools for women.
    Mertenskoetter T; Kaptur PE
    Eur J Med Res; 2011 Jan; 16(1):1-6. PubMed ID: 21345763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction therapy with enfuvirtide-based highly active antiretroviral therapy in a patient with acute HIV-1 infection.
    Polk C; Chan-Tack KM; Kopack AM; Amoroso A
    AIDS Patient Care STDS; 2007 Feb; 21(2):75-7. PubMed ID: 17328655
    [No Abstract]   [Full Text] [Related]  

  • 27. Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.
    Kashuba AD; Gengiah TN; Werner L; Yang KH; White NR; Karim QA; Abdool Karim SS
    J Acquir Immune Defic Syndr; 2015 Jul; 69(3):264-9. PubMed ID: 26181703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A tailored dose of tenofovir could reduce its impact on bone mass in HIV Type 1-infected children and adolescents: a report from 5 years of clinical experience.
    Rosso R; Parodi A; Torrisi C; De Terlizzi F; Viscoli C; Vignolo M
    AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1265-6. PubMed ID: 20874420
    [No Abstract]   [Full Text] [Related]  

  • 29. Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.
    Sokal DC; Karim QA; Sibeko S; Yende-Zuma N; Mansoor LE; Baxter C; Grobler A; Frolich J; Kharsany AB; Miya N; Mlisana K; Maarshalk S; Karim SS
    Antivir Ther; 2013; 18(3):301-10. PubMed ID: 22914267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients.
    Gazzard BG
    Expert Opin Pharmacother; 2006 Apr; 7(6):793-802. PubMed ID: 16556093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.
    Rosen RK; Morrow KM; Carballo-Diéguez A; Mantell JE; Hoffman S; Gai F; Maslankowski L; El-Sadr WM; Mayer KH
    J Womens Health (Larchmt); 2008 Apr; 17(3):383-92. PubMed ID: 18328009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Commentary: The place of tenofovir disoproxil fumarate in pediatric antiretroviral therapy.
    Havens PL; Hazra R
    Pediatr Infect Dis J; 2015 Apr; 34(4):406-8. PubMed ID: 25599283
    [No Abstract]   [Full Text] [Related]  

  • 33. FDA paves the way for pre-exposure HIV prophylaxis.
    Holmes D
    Lancet; 2012 Jul; 380(9839):325. PubMed ID: 22852138
    [No Abstract]   [Full Text] [Related]  

  • 34. Topical microbicides--what's new?
    Karim QA; Baxter C; Karim SA
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2():S144-9. PubMed ID: 23764627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tenofovir disoproxil fumarate.
    Antoniou T
    Drugs; 2003; 63(15):1609-10. PubMed ID: 12887266
    [No Abstract]   [Full Text] [Related]  

  • 36. Can AIDS drug also prevent HIV infection?
    AIDS Read; 2004 Jan; 14(1):14. PubMed ID: 14959699
    [No Abstract]   [Full Text] [Related]  

  • 37. Antiretroviral chemoprophylaxis: new successes and questions.
    Mayer KH
    Lancet; 2015 Jun; 385(9984):2236-7. PubMed ID: 25769358
    [No Abstract]   [Full Text] [Related]  

  • 38. [HIV therapy and adherence].
    Kuhlmann B
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():62-3. PubMed ID: 19024920
    [No Abstract]   [Full Text] [Related]  

  • 39. Least among equals.
    Kuritzkes DR; Hakim JG; Sanne I
    Clin Infect Dis; 2012 Mar; 54(6):876-7. PubMed ID: 22357810
    [No Abstract]   [Full Text] [Related]  

  • 40. After CAPRISA 004: time to re-evaluate the HIV lexicon.
    Cates W
    Lancet; 2010 Aug; 376(9740):495-6. PubMed ID: 20709216
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.